ClinicalTrials.gg
CompletedNCT03471078Updated Sep 28, 2023Results posted

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

A Phase 3 interventional study of Avatrombopag and Placebo Oral Tablet in Chemotherapy-induced Thrombocytopenia, sponsored by Sobi, Inc.. Completed at 55 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Sobi, Inc. · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.

Enrollment
8th of 23
122 · median 50
Started
2018
with 1 other
Phase 3
5 of 23
1 open now
Registered
8th of 23
by date
Lead sponsor
2 of 23
Sobi, Inc.

Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 3, and was the 8th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing avatrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.

Read the detailed description

Subjects will receive placebo controlled test treatment for one cycle of chemotherapy followed by an observational cycle. Subjects will have the option to continue into an open label extension period for all remaining chemotherapy cycles within the current regimen. After the follow-up visit, all subjects will continue to a long-term safety follow-up period.

03

Conditions studied

  • Chemotherapy-induced Thrombocytopenia

Browse trials for

Keywords

  • CIT
  • Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women greater than or equal to 18 years of age;
  • A diagnosis of ovarian, lung (small cell or non-small cell) or bladder cancer requiring systemic chemotherapy
  • Participant receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents:

    • Nucleoside analog, including gemcitabine and fluorouracil;
    • Carboplatin or cisplatin;
    • Anthracycline; or
    • Alkylating agent;
  • Participant experienced severe thrombocytopenia, defined as 2 counts \<50 x 109/L measured at least 24 hours apart, during the qualifying chemotherapy cycle, of their current chemotherapy regimen
  • performance status \<=2

Exclusion criteria

Exclusion Criteria:

  • Participant has experienced >=Grade 2 CIT other than during the current chemotherapy treatment regimen within 6 months of Screening;
  • Participant has any history of hematologic , including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases;
  • Participant has received >2 or is receiving whole brain radiation during the study treatment period;
  • Participant has a known medical history of genetic prothrombotic syndromes
  • Participant has a history of arterial or venous thrombosis within 3 months of screening;
  • Use of vitamin K antagonists;
  • Participant has previously received a thrombopoietin receptor agonist or recombinant human thrombopoietin for the treatment of CIT within 3 months of screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Avatrombopag

    Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.

    Drug: Avatrombopag

  • Placebo comparator
    Placebo

    Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.

    Drug: Placebo Oral Tablet

Interventions

  • Oral avatrombopag tablet

  • DrugPlacebo Oral Tablet

    Placebo comparator tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days

    Time frame: Randomization up to 33 days

Secondary outcomes

  1. Duration of Severe Thrombocytopenia Defined as a Platelet Count <50 x 10^9/L

    The duration of severe thrombocytopenia is defined as the total number of days with a platelet count \<50×10\^9/L during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day of Cycle X+2.

    Time frame: Randomization up to 33 days

  2. Change in Platelet Count From Baseline (Nadir)

    Comparison of avatrombopag 60 mg vs. placebo, adjusted for the number of chemotherapy agents currently receiving per IWRS (1, ≥2). Cycle X nadir is defined as the lowest platelet count value prior to the first dose of study drug; Cycle X+1 nadir is defined as the lowest platelet count value during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day in Cycle X+2.

    Time frame: Randomization up to 33 days

  3. Percentage of Subjects Who Did Not Have Major or Non-major Clinically Relevant Bleeding During the Period After Post-chemotherapy Study Drug Treatment in Cycle X+1 Through Chemotherapy Day of Cycle X+2.

    Time frame: Randomization up to 33 days

07

Results

Posted Nov 24, 2021

Participant flow

This was a Phase 3, randomized, double- blind, placebo controlled study of the efficacy and and safety of avatrombopag in subjects with chemotherapy induced thrombocytopenia and non active non-hematologic cancers. The study was conducted by qualified investigators at 71 sites in China, Hungary, Poland, Russia, Serbia, Ukraine, and the United States. The first subject was enrolled 12October2018.

Participant flow — Overall Study
MilestoneAvatrombopagPlacebo
Started8240
Completed6134
Not completed216
Withdrew: Withdrawal by subject91
Withdrew: Adverse event41
Withdrew: Physician decision32
Withdrew: Death20
Withdrew: Other32

Outcome measures

PrimaryPercentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days
Time frame:
Randomization up to 33 days
Reported as:
Count of participants · Participants
Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days
ParticipantsAvatrombopagPlacebo
Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days5729
Statistical analysis
  • Avatrombopag vs Placebo · Cochran-Mantel-Haenszel · p = 0.7186 · Mean difference (final values): -3.0 · 95% CI -21.7 to 15.6
SecondaryDuration of Severe Thrombocytopenia Defined as a Platelet Count <50 x 10^9/L

The duration of severe thrombocytopenia is defined as the total number of days with a platelet count \<50×10\^9/L during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day of Cycle X+2.

Time frame:
Randomization up to 33 days
Reported as:
Mean · Days
Duration of Severe Thrombocytopenia Defined as a Platelet Count <50 x 10^9/L
DaysAvatrombopagPlacebo
Duration of Severe Thrombocytopenia Defined as a Platelet Count <50 x 10^9/L4.6 ± 5.534.7 ± 6.56
Statistical analysis
  • Avatrombopag vs Placebo · Van Elteren Test · p = 0.8372
SecondaryChange in Platelet Count From Baseline (Nadir)

Comparison of avatrombopag 60 mg vs. placebo, adjusted for the number of chemotherapy agents currently receiving per IWRS (1, ≥2). Cycle X nadir is defined as the lowest platelet count value prior to the first dose of study drug; Cycle X+1 nadir is defined as the lowest platelet count value during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day in Cycle X+2.

Time frame:
Randomization up to 33 days
Reported as:
Mean · Platelets x 10^9/L
Change in Platelet Count From Baseline (Nadir)
Platelets x 10^9/LAvatrombopagPlacebo
Change in Platelet Count From Baseline (Nadir)51.5 ± 61.8529.1 ± 39.48
SecondaryPercentage of Subjects Who Did Not Have Major or Non-major Clinically Relevant Bleeding During the Period After Post-chemotherapy Study Drug Treatment in Cycle X+1 Through Chemotherapy Day of Cycle X+2.
Time frame:
Randomization up to 33 days
Reported as:
Count of participants · Participants
Percentage of Subjects Who Did Not Have Major or Non-major Clinically Relevant Bleeding During the Period After Post-chemotherapy Study Drug Treatment in Cycle X+1 Through Chemotherapy Day of Cycle X+2.
ParticipantsAvatrombopagPlacebo
Percentage of Subjects Who Did Not Have Major or Non-major Clinically Relevant Bleeding During the Period After Post-chemotherapy Study Drug Treatment in Cycle X+1 Through Chemotherapy Day of Cycle X+2.8240

Adverse events

Collected over Adverse event data were collected during the Double-Blind Treatment Phase and included two 21- or 28-day chemotherapy cycles.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avatrombopag2/82 (2.4%)16/82 (19.5%)71/82 (86.6%)
Placebo0/40 (0%)8/40 (20%)36/40 (90%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventAvatrombopagPlacebo
ThrombocytopeniaBlood and lymphatic system disorders4/824/40
AnaemiaBlood and lymphatic system disorders1/822/40
NeutropeniaBlood and lymphatic system disorders0/822/40
PancytopeniaBlood and lymphatic system disorders3/820/40
LeukopeniaBlood and lymphatic system disorders1/821/40
PneumoniaInfections and infestations1/821/40
Cerebral ischaemiaNervous system disorders0/821/40
Febrile neutropeniaBlood and lymphatic system disorders1/820/40
LeukocytosisBlood and lymphatic system disorders1/820/40
StomatitisGastrointestinal disorders1/820/40
Most frequent other events
Most frequent other events
EventAvatrombopagPlacebo
AnaemiaBlood and lymphatic system disorders32/8221/40
NeutropeniaBlood and lymphatic system disorders24/8217/40
LeukopeniaBlood and lymphatic system disorders24/8215/40
ThrombocytopeniaBlood and lymphatic system disorders15/8213/40
NauseaGastrointestinal disorders6/826/40
ThombocytosisBlood and lymphatic system disorders9/822/40
AstheniaGeneral disorders5/824/40
FatigueGeneral disorders3/823/40
VomitingGastrointestinal disorders5/820/40
EpistaxisRespiratory, thoracic and mediastinal disorders4/822/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)AvatrombopagPlaceboTotal
Age at Enrollment61.0 ± 10.0860.8 ± 10.4161.0 ± 10.15
Sex: Female, Male
Sex: Female, Male(Participants)AvatrombopagPlaceboTotal
Female432265
Male391857
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AvatrombopagPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino7837115
Unknown or Not Reported437
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AvatrombopagPlaceboTotal
American Indian or Alaska Native000
Asian538
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7737114
More than one race000
Unknown or Not Reported000
ECOG Performance Status
ECOG Performance Status(Participants)AvatrombopagPlaceboTotal
Subjects with ECOG Score 021829
Subjects with ECOG Score 1603191
Subjects with ECOG Score 2112
Number of Eligible Chemotherapy Agents Currently Receiving per IWRS
Number of Eligible Chemotherapy Agents Currently Receiving per IWRS(Participants)AvatrombopagPlaceboTotal
Subjects Receiving 1 Agent402060
Subjects Receiving ≥ 2 Agents422062
Baseline Platelet Count (x10⁹/L)
Baseline Platelet Count (x10⁹/L)(platelets x10⁹/L)AvatrombopagPlaceboTotal
Mean29.6 ± 13.6633.0 ± 11.4930.7 ± 13.04
Height (cm)
Height (cm)(cm)AvatrombopagPlaceboTotal
Mean166.3 ± 10.17166.2 ± 10.32166.3 ± 10.18

2 further baseline measures are reported on the registry.

08

Study locations

55 sites
  • Dova Site
    Anaheim, California 92801, United States
  • Dova Site
    Bakersfield, California 93309, United States
  • Dova Site
    Riverside, California 92501, United States
  • Dova Site
    Santa Monica, California 90403, United States
  • Dova Site
    Augusta, Georgia 30912, United States
  • Dova Site
    Harvey, Illinois 60426, United States
  • Dova Site
    Skokie, Illinois 60076, United States
  • Dova Site
    Bloomington, Indiana 47403, United States
  • Dova Site
    Wichita, Kansas 67214, United States
  • Dova Site
    Ashland, Kentucky 41101, United States
  • Dova Site
    Boston, Massachusetts 02114, United States
  • Dova Site
    Minneapolis, Minnesota 55417, United States
  • Dova Site
    Canton, Ohio 44718, United States
  • Dova Site
    Gettysburg, Pennsylvania 17325, United States
  • Dova Site
    Harbin, China
  • Dova Site
    Linyi, China
  • Dova Site
    Neijiang, China
  • Dova Site
    Shanghai, China
  • Dova Site
    Tianjin, China
  • Dova Site
    Budapest, Hungary
  • Dova Site
    Debrecen, Hungary
  • Dova Site
    Nyiregyhaza, Hungary
  • Dova Site
    Törökbálint, Hungary
  • Dova Site
    Lublin, Poland
  • Dova Site
    Olsztyn, Poland
  • Dova Site
    Prabuty, Poland
  • Dova Site
    Tomaszów Mazowiecki, Poland
  • Dova Site
    Warsaw, Poland
  • Dova Site
    Arkhangel'sk, Russian Federation
  • Dova Site
    Kazan, Russian Federation
  • Dova Site
    Kursk, Russian Federation
  • Dova Site
    Moscow, Russian Federation
  • Dova Site
    Novosibirsk, Russian Federation
  • Dova Site
    Omsk, Russian Federation
  • Dova Site
    Pyatigorsk, 357502, Russian Federation
  • Dova Site
    Saint Petersburg, 188663, Russian Federation
  • Dova Site
    Saint Petersburg, Russian Federation
  • Dova Site
    Saransk, Russian Federation
  • Dova Site
    Sochi, Russian Federation
  • Dova Site
    Belgrade, Serbia
  • Dova Site
    Kragujevac, Serbia
  • Dova Site
    Sremska Kamenica, Serbia
  • Dova Site
    Cherkasy, Ukraine
  • Dova Site
    Chernihiv, Ukraine
  • Dova Site
    Chernivtsi, Ukraine
  • Dova Site
    Ivano-Frankivs'k, Ukraine
  • Dova Site
    Kharkiv, Ukraine
  • Dova Site
    Kherson, Ukraine
  • Dova Site
    Kropyvnytskyi, Ukraine
  • Dova Site
    Kyiv, Ukraine
  • Dova Site
    Odesa, Ukraine
  • Dova Site
    Sumy, Ukraine
  • Dova Site
    Ternopil', Ukraine
  • Dova Site
    Uzhhorod, Ukraine
  • Dova Site
    Vinnytsia, Ukraine
09

References and documents

Publications

  • Al-Samkari H, Kolb-Sielecki J, Safina SZ, Xue X, Jamieson BD. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2022 Mar;9(3):e179-e189. doi: 10.1016/S2352-3026(22)00001-1. PubMed 35240074 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2020, 22 months.

Results were first posted in Nov 2021, 1 year 2 months after primary completion.

Of 29 phase 3 interventional studies under Thrombocytopenia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 45. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2018
First posted
Mar 20, 2018
StartActual
Oct 12, 2018
Primary completionActual
Aug 28, 2020
CompletionActual
Jan 31, 2023
Results first posted
Nov 24, 2021
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03471078
Lead sponsor
Sobi, Inc.
Responsible party
Sponsor
First posted
Mar 20, 2018
Start date
Oct 12, 2018
Primary completion
Aug 28, 2020
Completion
Jan 31, 2023
Results posted
Nov 24, 2021
Last update
Sep 28, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion